What Aisling Capital does

Aisling Capital is a New York-based healthcare-focused venture capital and private equity firm founded in 2000 by Dennis Purcell. The firm manages over $1.8 billion in committed capital across four to five funds, deploying capital into biopharmaceuticals, medical devices, diagnostics, and healthcare services companies via seed and venture financings, small-cap public equities, structured debt and royalty deals, and leveraged buyouts. Its investment team of 8+ professionals combines 150+ years of healthcare industry experience across clinical, operational, and financial disciplines, supplemented by three MD-level Operating Partners who have served as executives and board members of portfolio companies including Loxo Oncology and Marinus Pharmaceuticals.

The firm's portfolio spans development-stage and public companies across multiple therapeutic modalities, including oncology (BridgeBio Oncology Therapeutics, Bicara Therapeutics, Monte Rosa Therapeutics), psychedelic medicine (COMPASS Pathways), gene therapy manufacturing (Forge Biologics), and stem cell technology (Garuda Therapeutics). Notable exits include Loxo Oncology's acquisition by Eli Lilly for approximately $8 billion and ZELTIQ's acquisition by Allergan for approximately $2.4 billion. Aisling generates revenue through conventional fund management economics: management fees on committed capital and carried interest on investment profits, distributed to more than 90 institutional limited partners including pension funds, endowments, and family offices. The firm maintains a single headquarters at 489 5th Avenue in New York and is registered as an investment adviser (Aisling Capital Management LP) with the U.S. Securities and Exchange Commission.

Name

Aisling Capital

Legal name

Aisling Capital Management LP

Website

http://www.aislingcapital.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Aisling Capital is a New York-based healthcare-focused venture capital and private equity firm founded in 2000 that manages over $1.8 billion across multiple funds, investing in biopharmaceutical, medical device, diagnostics, and healthcare services companies and serving more than 90 institutional limited partners.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Debt Providers (FSANAAAL)

Keywords

• Healthcare venture capital
• Life sciences investment
• Biopharmaceutical financing
• Private equity healthcare
• Growth equity investments

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Investment Management: Aisling Capital generates returns through management fees on committed capital and carried interest on investment profits. The firm has raised over $1.8 billion across multiple funds since 2000, investing in development-stage companies, public equities, structured debt, and buyouts across the life sciences industry.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Aisling Capital is a private investment firm that manages committed capital across multiple funds and deploys it into healthcare and life sciences companies. The firm invests in biopharmaceutical, medical device, diagnostics, and healthcare services businesses through seed and venture financings, small-cap public equities, structured debt and royalty deals, and large-cap leveraged buyouts, while providing active strategic guidance to portfolio company management teams.

Product overview

Aisling Capital is a healthcare investment firm that invests in companies developing and commercializing innovative healthcare products, services, and technologies. The firm does not offer a single unified product or platform; rather, it manages a diversified portfolio of biopharmaceutical, biotechnology, medical device, diagnostics, and healthcare services companies. As an investment management entity, Aisling Capital's offerings consist of investment funds and strategic guidance to portfolio companies rather than standalone software products or services.

Differentiator

Problem solved

Functional benefit

Products and services

• Aisling Capital Healthcare Investment Funds
• Strategic Guidance and Active Portfolio Engagement

Quantifiable outcome

• Multiple successful portfolio company exits including Loxo Oncology acquired by Eli Lilly for approximately $8 billion, ZELTIQ acquired by Allergan for approximately $2.4 billion, and numerous other acquisitions

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Atlas Venture: Early-stage healthcare and biotech venture firm building companies from inception. Comparable in clinical-credentialed team and focus on formation-stage biotech investing.
• New Leaf Venture Partners: Healthcare-focused venture and growth firm investing in biopharma and medical devices. Comparable in therapeutic-area breadth and stage-spanning strategy within healthcare.
• OrbiMed Advisors: Healthcare-dedicated investment firm managing ~$17B across venture, growth, and public equity strategies. Directly comparable to Aisling given its stage-spanning healthcare investing approach and clinical-scientific team orientation.
• Deerfield Management: Healthcare-focused investment firm with venture, growth, and structured credit capabilities, managing ~$15B. Comparable to Aisling as a multi-strategy healthcare investor participating in similar rounds (e.g., co-investor in CalciMedica).
• Cormorant Asset Management: Healthcare/biotech-focused hedge fund and private investor that frequently co-invests with Aisling (e.g., BBOT financing). Comparable as a healthcare specialist deploying capital across stages with deep biotech networks.
• Omega Funds: Healthcare-focused investment firm investing across private and public healthcare companies. Co-led the BBOT financing alongside Cormorant with Aisling participating, reflecting direct co-investment overlap.
• RA Capital Management: Healthcare-focused crossover fund investing across public and private life sciences companies. Comparable stage-spanning strategy and clinical diligence approach as Aisling.
• Baker Bros. Advisors: Healthcare/biotech-focused long-only adviser founded by brothers with PhDs, managing multi-billion AUM. Comparable clinical-scientific orientation and concentrated life sciences investment mandate.
• Frazier Healthcare Partners: Healthcare-dedicated venture and growth equity firm with $4B+ AUM. Comparable in stage-spanning healthcare focus and operating-partner-style support for portfolio companies.
• Braidwell LP: Healthcare-dedicated investment firm co-leading rounds like Bicara Therapeutics' $165M Series C with Aisling participating. Directly comparable as a healthcare-focused investor in similar therapeutic areas.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/AislingInvestor
• LinkedInlinkedin.com/company/974274

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments185 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aisling Capital